Hepatocellular carcinoma (HCC) is the most common primary liver cancer and its diagnosis on routine stains is usually straightforward, except in some cases where there may be difficulty in distinguishing HCCs from metastatic carcinomas (MC) and cholangiocarcinomas (CC). Hepatocyte Paraffin 1 antibody (Hep Par 1) is a new monoclonal antibody which reacts with normal and neoplastic hepatocytes, and this study aims to determine its specificity and sensitivity in distinguishing hepatocellular carcinoma (HCC) from cholangiocarcinoma (CC) and metastatic carcinomas (MC). Hep Par 1 antibody was applied to 28 cases of HCC, 22 cases of MC from varying sites and 8 CCs, and produced a strong, diffuse, granular, cytoplasmic staining of all benign...
Objective: It is challenging and difficult to differentiate primary from metastatic hepatic masses s...
To assess the diagnostic utility of glypican-3 (GPC-3) in comparison to Hep Par 1 in the diagnosis o...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and metas...
Hepatocyte paraffin 1 is a monoclonal antibody that has been developed specifically to react with he...
Hepatocyte paraffin 1 is a monoclonal antibody that has been developed specifically to react with he...
Introduction. A variety of primary and secondary malignant tumours may present in the liver. In clin...
Background: This study was aimed at evaluating the correlation between Hepatocyte paraffin 1 (Hep pa...
Objective: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), a-fetopro...
Background: This study was aimed at evaluating the correlation between Hepatocyte paraffin 1 (Hep pa...
In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic charac...
Hepatocellular carcinoma (HCC) exerts huge effects on the health burden of the world because of its ...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and meta...
Aim. Differential immunohistochemical parameters of primary liver cancer and liver metastases of duc...
A library of monoclonal antibodies (MoAbs) has been produced against a human hepatocellular carcinom...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and meta...
Objective: It is challenging and difficult to differentiate primary from metastatic hepatic masses s...
To assess the diagnostic utility of glypican-3 (GPC-3) in comparison to Hep Par 1 in the diagnosis o...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and metas...
Hepatocyte paraffin 1 is a monoclonal antibody that has been developed specifically to react with he...
Hepatocyte paraffin 1 is a monoclonal antibody that has been developed specifically to react with he...
Introduction. A variety of primary and secondary malignant tumours may present in the liver. In clin...
Background: This study was aimed at evaluating the correlation between Hepatocyte paraffin 1 (Hep pa...
Objective: To investigate immunohistochemical staining of hepatocyte paraffin-1 (HepPar1), a-fetopro...
Background: This study was aimed at evaluating the correlation between Hepatocyte paraffin 1 (Hep pa...
In order to classify the hepatocellular carcinomas (HCCs) which had diverse clinicopathologic charac...
Hepatocellular carcinoma (HCC) exerts huge effects on the health burden of the world because of its ...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and meta...
Aim. Differential immunohistochemical parameters of primary liver cancer and liver metastases of duc...
A library of monoclonal antibodies (MoAbs) has been produced against a human hepatocellular carcinom...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and meta...
Objective: It is challenging and difficult to differentiate primary from metastatic hepatic masses s...
To assess the diagnostic utility of glypican-3 (GPC-3) in comparison to Hep Par 1 in the diagnosis o...
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and metas...